TRATTAMENTO NEOADJUVANTE DEL SARCOMA DI EWING

RISULTATI OTTENUTI IN 112 PAZIENTI TRATTATI CON UN PROTOCOLLO CHEMIOTERAPICO A 6 FARMACI (VINCRISTINA, ADRIAMICINA, CICLOFOSFAMIDE, DEACTINOMICINA, IFOSFAMIDE ED ETOPOSIDE)

Translated title of the contribution: Neoadjuvant treatment for Ewing's sarcoma: Results in 112 patients treated with a 6 drugs chemotherapy protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)

G. Bacci, S. Ferrari, P. Rosito, E. Barbieri, M. Mercuri, A. Brach Del Prever, D. Iantorno, C. Forni, M. Campanacci

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

From January 1988 to October 1991, one hundred and twelve patients with non metastatic Ewing's sarcoma of bone were treated with a 6 drugs neoadjuvant chemotherapy protocol (IOR/Ew2) in which, to the four drugs usually used in the treatment of this tumor (vincristine, adriamycin, cyclophosphamide and dactinomycin). Ifosfamide and VP-16 were added. The local treatment consisted of radiation therapy in 52 cases, a surgical treatment was performed in 27 cases and in the remaining 33 cases both the previous treatments were used. At a mean follow-up of 4.5 years (3-6.5), 62 patients (55.3%), remained continuously free of disease and 50 relapsed: 41 with metastases, 8 with metastases and local recurrence and 1 with local recurrence alone. These results do not differ from the ones obtained in our Institution in 98 patients treated between 1983 and 1988 with a neoadjuvant protocol (IOR/Ew1) in which only VCR, ADM, CTX and actD were used (3 year CDFs: IOR/Ew2 = 60.7% - IOR/Ew1 = 55.1%). In IOR/Ew2 a higher DFS rate was observed in the patients with tumor located in the axile bones in comparison with that obtained in the previous study (IOR/Ew2 = 48.6%, IOR Ew1 = 25.6%). Despite the fact that these results came from a non-randomized study, the authors conclude that the addition of Ifosfamide and VP-16 to the four drugs standard regimen do not improve the outcome of patients with Ewing's sarcoma of bone, with the possible exception of the patients with tumor located in the axile bones. This data should be confirmed in further and larger studies.

Original languageItalian
Pages (from-to)457-469
Number of pages13
JournalMinerva Pediatrica
Volume47
Issue number11
Publication statusPublished - 1995

Fingerprint

Ifosfamide
Ewing's Sarcoma
Neoadjuvant Therapy
Dactinomycin
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Drug Therapy
Pharmaceutical Preparations
Bone and Bones
Neoplasm Metastasis
Recurrence
Neoplasms
Therapeutics
Radiotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

TRATTAMENTO NEOADJUVANTE DEL SARCOMA DI EWING : RISULTATI OTTENUTI IN 112 PAZIENTI TRATTATI CON UN PROTOCOLLO CHEMIOTERAPICO A 6 FARMACI (VINCRISTINA, ADRIAMICINA, CICLOFOSFAMIDE, DEACTINOMICINA, IFOSFAMIDE ED ETOPOSIDE). / Bacci, G.; Ferrari, S.; Rosito, P.; Barbieri, E.; Mercuri, M.; Brach Del Prever, A.; Iantorno, D.; Forni, C.; Campanacci, M.

In: Minerva Pediatrica, Vol. 47, No. 11, 1995, p. 457-469.

Research output: Contribution to journalArticle

Bacci, G. ; Ferrari, S. ; Rosito, P. ; Barbieri, E. ; Mercuri, M. ; Brach Del Prever, A. ; Iantorno, D. ; Forni, C. ; Campanacci, M. / TRATTAMENTO NEOADJUVANTE DEL SARCOMA DI EWING : RISULTATI OTTENUTI IN 112 PAZIENTI TRATTATI CON UN PROTOCOLLO CHEMIOTERAPICO A 6 FARMACI (VINCRISTINA, ADRIAMICINA, CICLOFOSFAMIDE, DEACTINOMICINA, IFOSFAMIDE ED ETOPOSIDE). In: Minerva Pediatrica. 1995 ; Vol. 47, No. 11. pp. 457-469.
@article{aa4f49909d7a400a9f39b2d2fc56a2e7,
title = "TRATTAMENTO NEOADJUVANTE DEL SARCOMA DI EWING: RISULTATI OTTENUTI IN 112 PAZIENTI TRATTATI CON UN PROTOCOLLO CHEMIOTERAPICO A 6 FARMACI (VINCRISTINA, ADRIAMICINA, CICLOFOSFAMIDE, DEACTINOMICINA, IFOSFAMIDE ED ETOPOSIDE)",
abstract = "From January 1988 to October 1991, one hundred and twelve patients with non metastatic Ewing's sarcoma of bone were treated with a 6 drugs neoadjuvant chemotherapy protocol (IOR/Ew2) in which, to the four drugs usually used in the treatment of this tumor (vincristine, adriamycin, cyclophosphamide and dactinomycin). Ifosfamide and VP-16 were added. The local treatment consisted of radiation therapy in 52 cases, a surgical treatment was performed in 27 cases and in the remaining 33 cases both the previous treatments were used. At a mean follow-up of 4.5 years (3-6.5), 62 patients (55.3{\%}), remained continuously free of disease and 50 relapsed: 41 with metastases, 8 with metastases and local recurrence and 1 with local recurrence alone. These results do not differ from the ones obtained in our Institution in 98 patients treated between 1983 and 1988 with a neoadjuvant protocol (IOR/Ew1) in which only VCR, ADM, CTX and actD were used (3 year CDFs: IOR/Ew2 = 60.7{\%} - IOR/Ew1 = 55.1{\%}). In IOR/Ew2 a higher DFS rate was observed in the patients with tumor located in the axile bones in comparison with that obtained in the previous study (IOR/Ew2 = 48.6{\%}, IOR Ew1 = 25.6{\%}). Despite the fact that these results came from a non-randomized study, the authors conclude that the addition of Ifosfamide and VP-16 to the four drugs standard regimen do not improve the outcome of patients with Ewing's sarcoma of bone, with the possible exception of the patients with tumor located in the axile bones. This data should be confirmed in further and larger studies.",
keywords = "adriamycin, cyclophosphamide, dactinomycin, etoposide, Ewing's sarcoma, ifosfamid e, protocol drug therapy, vincristine",
author = "G. Bacci and S. Ferrari and P. Rosito and E. Barbieri and M. Mercuri and {Brach Del Prever}, A. and D. Iantorno and C. Forni and M. Campanacci",
year = "1995",
language = "Italian",
volume = "47",
pages = "457--469",
journal = "Minerva Pediatrica",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "11",

}

TY - JOUR

T1 - TRATTAMENTO NEOADJUVANTE DEL SARCOMA DI EWING

T2 - RISULTATI OTTENUTI IN 112 PAZIENTI TRATTATI CON UN PROTOCOLLO CHEMIOTERAPICO A 6 FARMACI (VINCRISTINA, ADRIAMICINA, CICLOFOSFAMIDE, DEACTINOMICINA, IFOSFAMIDE ED ETOPOSIDE)

AU - Bacci, G.

AU - Ferrari, S.

AU - Rosito, P.

AU - Barbieri, E.

AU - Mercuri, M.

AU - Brach Del Prever, A.

AU - Iantorno, D.

AU - Forni, C.

AU - Campanacci, M.

PY - 1995

Y1 - 1995

N2 - From January 1988 to October 1991, one hundred and twelve patients with non metastatic Ewing's sarcoma of bone were treated with a 6 drugs neoadjuvant chemotherapy protocol (IOR/Ew2) in which, to the four drugs usually used in the treatment of this tumor (vincristine, adriamycin, cyclophosphamide and dactinomycin). Ifosfamide and VP-16 were added. The local treatment consisted of radiation therapy in 52 cases, a surgical treatment was performed in 27 cases and in the remaining 33 cases both the previous treatments were used. At a mean follow-up of 4.5 years (3-6.5), 62 patients (55.3%), remained continuously free of disease and 50 relapsed: 41 with metastases, 8 with metastases and local recurrence and 1 with local recurrence alone. These results do not differ from the ones obtained in our Institution in 98 patients treated between 1983 and 1988 with a neoadjuvant protocol (IOR/Ew1) in which only VCR, ADM, CTX and actD were used (3 year CDFs: IOR/Ew2 = 60.7% - IOR/Ew1 = 55.1%). In IOR/Ew2 a higher DFS rate was observed in the patients with tumor located in the axile bones in comparison with that obtained in the previous study (IOR/Ew2 = 48.6%, IOR Ew1 = 25.6%). Despite the fact that these results came from a non-randomized study, the authors conclude that the addition of Ifosfamide and VP-16 to the four drugs standard regimen do not improve the outcome of patients with Ewing's sarcoma of bone, with the possible exception of the patients with tumor located in the axile bones. This data should be confirmed in further and larger studies.

AB - From January 1988 to October 1991, one hundred and twelve patients with non metastatic Ewing's sarcoma of bone were treated with a 6 drugs neoadjuvant chemotherapy protocol (IOR/Ew2) in which, to the four drugs usually used in the treatment of this tumor (vincristine, adriamycin, cyclophosphamide and dactinomycin). Ifosfamide and VP-16 were added. The local treatment consisted of radiation therapy in 52 cases, a surgical treatment was performed in 27 cases and in the remaining 33 cases both the previous treatments were used. At a mean follow-up of 4.5 years (3-6.5), 62 patients (55.3%), remained continuously free of disease and 50 relapsed: 41 with metastases, 8 with metastases and local recurrence and 1 with local recurrence alone. These results do not differ from the ones obtained in our Institution in 98 patients treated between 1983 and 1988 with a neoadjuvant protocol (IOR/Ew1) in which only VCR, ADM, CTX and actD were used (3 year CDFs: IOR/Ew2 = 60.7% - IOR/Ew1 = 55.1%). In IOR/Ew2 a higher DFS rate was observed in the patients with tumor located in the axile bones in comparison with that obtained in the previous study (IOR/Ew2 = 48.6%, IOR Ew1 = 25.6%). Despite the fact that these results came from a non-randomized study, the authors conclude that the addition of Ifosfamide and VP-16 to the four drugs standard regimen do not improve the outcome of patients with Ewing's sarcoma of bone, with the possible exception of the patients with tumor located in the axile bones. This data should be confirmed in further and larger studies.

KW - adriamycin

KW - cyclophosphamide

KW - dactinomycin

KW - etoposide

KW - Ewing's sarcoma

KW - ifosfamid e

KW - protocol drug therapy

KW - vincristine

UR - http://www.scopus.com/inward/record.url?scp=0029618319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029618319&partnerID=8YFLogxK

M3 - Articolo

VL - 47

SP - 457

EP - 469

JO - Minerva Pediatrica

JF - Minerva Pediatrica

SN - 0026-4946

IS - 11

ER -